Research Contracts and Commercialisation

Contracts and Compliance Management

The Contracts and Compliance (C&C) team supports NCCS research efforts by drafting, reviewing, negotiating, coordinating signings, and performing relevant administrative functions regarding research related agreements. C&C further supports NCCS’ cancer research in matters related to HBRA, PDPA and data governance by establishing appropriate processes and policies for exchanges of research materials, confidential information, data, technical know-how and equipment.

C&C provides information and support to NCCS researchers and clinicians engaged in research activities with industrial and academic collaborators and ensures that all research agreements comply with NCCS and SingHealth policies, regulatory requirements, MOH guidelines and policies, as well as applicable local and international laws. Matters that C&C assists with negotiating in that arise from research agreements include, but are not limited to, publication rights, intellectual property rights, confidentiality obligations, data protection, and liability issues.

C&C handles the following types of agreements:

Non-Disclosure or Confidential Disclosure Agreements (NDA or CDA)
Project Agreements (PA)
Research Collaboration Agreements (RCA)
Data Sharing and Material Transfer Agreements (DSMTA)
Memorandums of Understanding (MOU)

Technology Development and Commercialisation

The NCCS Technology Development & Commercialisation (TD&C) office seeks to pursue the commercialisation of NCCS’s research outcomes and engagement of commercial partners for R&D collaborations. Our goal is to maximise the amount of NCCS research intellectual property and technology that reaches the market and benefits patients globally – whether developed internally at the institute to spin off or co-developed with commercial partners.

NCCS researchers continuously produce world-class results that have received widespread international recognition. In addition to generating an impressive publication track record and a growing reputation, the outcomes of this research include commercially promising technologies comprising multiple technology types - therapeutics development, target identification, diagnostics, biomarkers, artificial intelligence and related software, medical device development and support services for in-patient and in-home; all of which we are looking to bring to market either via licensing to industry or dedicated spin-offs.

TD&C is involved in external communications with key stakeholders in the industry regarding R&D collaborations and commercialisation. We aim to attract more industrial partners to form collaborations with NCCS and to license NCCS-developed technology. TD&C forms a channel through which enquiries regarding such potential external collaborations and licensing flow in and reach NCCS research staff, as well as being central to facilitating, formalising, and overseeing collaborative research activities as they take place.

NCCS TD&C seeks to engage any party, industrial or academic, which has an interest in collaborating with NCCS on commercially oriented oncology related research projects*. We can provide information regarding NCCS’s research interests and capabilities, potentially commercialisable research currently underway and licensable IP, our common models of collaboration and potential industrial collaboration-oriented grant funding mechanisms, as well as arrange for more in-depth contacts with NCCS researchers and clinicians.

If you have an interest in working with NCCS to develop promising oncology related products and bringing novel solutions to patients, we welcome your enquiry and look forward to hearing from you.

*For clinical trial specific projects, there is a separate, dedicated clinical trial team. Please contact our clinical trials office for more information.